Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Accounts Payables (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Accounts Payables for 8 consecutive years, with $4.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables fell 41.13% year-over-year to $4.2 million, compared with a TTM value of $4.2 million through Dec 2025, down 41.13%, and an annual FY2025 reading of $4.2 million, down 41.13% over the prior year.
  • Accounts Payables was $4.2 million for Q4 2025 at Arcturus Therapeutics Holdings, down from $5.5 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $19.3 million in Q1 2023 and bottomed at $4.2 million in Q4 2025.
  • Average Accounts Payables over 5 years is $9.9 million, with a median of $9.6 million recorded in 2022.
  • The sharpest move saw Accounts Payables surged 136.36% in 2023, then tumbled 52.73% in 2024.
  • Year by year, Accounts Payables stood at $10.1 million in 2021, then decreased by 25.94% to $7.4 million in 2022, then dropped by 29.13% to $5.3 million in 2023, then skyrocketed by 36.28% to $7.2 million in 2024, then tumbled by 41.13% to $4.2 million in 2025.
  • Business Quant data shows Accounts Payables for ARCT at $4.2 million in Q4 2025, $5.5 million in Q3 2025, and $10.6 million in Q2 2025.